CN106728036A - A kind of pharmaceutical composition for preventing and treating periodontitis - Google Patents

A kind of pharmaceutical composition for preventing and treating periodontitis Download PDF

Info

Publication number
CN106728036A
CN106728036A CN201611133168.5A CN201611133168A CN106728036A CN 106728036 A CN106728036 A CN 106728036A CN 201611133168 A CN201611133168 A CN 201611133168A CN 106728036 A CN106728036 A CN 106728036A
Authority
CN
China
Prior art keywords
ethanol
pharmaceutical composition
weight
weight portion
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611133168.5A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Haoyu Qingtian Medicine Technology Co ltd
Original Assignee
Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Haoyu Qingtian Medicine Technology Co ltd filed Critical Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority to CN201611133168.5A priority Critical patent/CN106728036A/en
Publication of CN106728036A publication Critical patent/CN106728036A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Pharmaceutical composition of periodontitis and preparation method thereof is prevented and treated the invention discloses a kind of, pharmaceutical composition of the present invention is with Herba oxygraphis glacialis, Oblongleaf Heterostemma, secondary rattan, trifolirhizin, cucurbitacin L, Homoplantaginin as bulk drug, proportioning is formed, routinely various formulations can be made by preparation process, prevent and treat periodontitis evident in efficacy.

Description

A kind of pharmaceutical composition for preventing and treating periodontitis
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly to a kind of pharmaceutical composition for preventing and treating periodontitis and its preparation side Method.
Background technology
Periodontitis is the destructive disease of periodontium, its shape for being mainly characterized by bleeding gums and inflammation and oral pocket It is inflammatory states of periodontal soft tissue and anti-to the direct immunization of plaque into the absorption with alveolar bone and tooth mobility etc. Should..Periodontitis is a multi-factor disease, and its cause of disease and pathogenesis are sufficiently complex.Modern medicine think in bacterial plaque bacterium and Its product is the initiation factor of periodontosis, and the defense reaction of other some local factors and host is also sent out periodontosis Exhibition produces important influence.Numerous studies show:Periodontal infection is probably angiocardiopathy, complications of pregnancy, respiratory tract sense The hazards of the general diseases such as dye, diabetes；And on the other hand, some general diseases such as diabetes or situation such as immunity It is low etc., there is significant impact to periodontosis.Focus on directed toward bacteria venereal disease in treatment because of, mechanical removal bacterial plaque and calculus dentalis Method include scaling, scrape control, root planing (scaling and root planing, SRP) etc., be treatment periodontosis, anti- Topmost, the simple and effective means that only it recurs.Sent out with to the periodontosis cause of disease and the further research for developing The defense reaction of existing host, host is to determine whether disease occurs to the neurological susceptibility of periodontosis in other words, and disease process and The necessary condition for lapsing to, so that we may include Chinese medicine and/or Western medicine to aid in removing virulence factor using some medicines Or the pathologic process of blocking periodontosis, so as to the purpose for reaching treatment periodontosis, reducing recurrence of periodontal disease.TCM investigation shows, Suffer from patients with periodontitis has significant relation with diet usually.Pungent stimulation food and drinking causes to stop up in stomach fire, warm blood wound And gum meat blood network, gum meat corruption purulence blood ooze out, long then gum wither root dew.Other TCM investigation shows, kidney deficiency person, its kidney essence deficiency, Sclerotin withers soft, causes tooth mobility.The use of a large amount of anti-anaerobic agents, not only erious adverse reaction, and resistance in clinical at present Property constantly strengthens, and is gradually limited to.
Periodontitis is one of common periodontal mouth disease, and the incidence of disease is high, is the main cause of adult's pathologic missing tooth. Multinomial research at present confirms that periodontitis is related to the infection of numerous pathogenic bacteria, and the aggregation of pathogenic bacteria causes the mistake of periodontal Tiny ecosystem Adjust, flora imbalance is so as to cause the generation of periodontitis.Having research confirms that whole body application antibacterials are used as the auxiliary of periodontitis treatment Helping therapy has certain curative effect, but its adverse reaction is also very important, such as gastrointestinal reaction, systemic anaphylaxis, flora imbalance, resistance Property etc.；Chinese medicine has one as the householder method that host immunity is adjusted in periodontitis treatment on treatment periodontitis treatment Fixed advantage, and curative effect affirms that development prospect is wide.
Herba oxygraphis glacialis：This product is Ranunculaceae Herba oxygraphis glacialis platymiscium Herba oxygraphis glacialis Oxygraphis glacialis (Fisch.) The herb of Bunpe [Ficaria glacialis Fisch.ex DC.].The 7-8 months pick flowers or herb, clean, and dry.【Nature and flavor】 Mildly bitter flavor；It is cold in nature.【Return through】Lung；Liver Channel.【Indication】Stasis-dispelling and pain-killing；Heat-clearing and damp-drying drug；Removing toxic substances.Main head injury；Hemostasis aches Bitterly；Sore.【Proterties】Rhizome is shorter, diameter 3-6mm.Fibrous root is grown thickly, brown to dark brown, and long up to 20cm, diameter is less than 1mm, the vertical straight burr of tool；Plane of rupture brown.Leafage life, yellow green, blade oval or Long Circle, 0.2-2.8cm long, 0.5- wide 2.2cm；Petiole 1-4cm long, narrow wing is arranged at top.Flower shrinkage is agglomerating, sepal 5, subcircular, yellow green；Petal brown, takes off sometimes Fall, stamen is most.Gas is fragrant, taste is pungent.Record in dictionary of medicinal plant.
Oblongleaf Heterostemma：This product is dicotyledon medicine Asclepiadaceae Winged Heterostemma platymiscium Oblongleaf Heterostemma Hetrostemma The complete stool of oblongifolium Cost..Autumn harvests, and dries.【Nature and flavor】It is slight bitter, sweet；It is flat.【Return through】Liver Channel.【Function master Control】Lactagogue.Qi and blood stasis after main product；Agalactia.【Former phytomorph】Weak winding liana.Complete stool has milk, and stem is by 2 row Pubescence.Leaf opposite；Petiole 2-4cm long；Blade Long Circle, dilute ovate Long Circle, 7.5-11cm long, 3.5-4.5cm wide, tip is sharp Point, basal circular；Per side 5-7 bars, arc rises lateral vein.Umbrella shape shape cyme axillary, 2-3cm long is blossomed 4-5；Calyx 5 Drastic crack, inner face base portion has body of gland about 10；Corolla outside light green, inner face yellow, spoke shape, diameter 1-1.5cm；Corolla splits levies 5, Cover to the right；Paracorolla five-pointed star aristiform, the every room 1 of massula, square circular, uprightly.Follicle radish fruit wire lanceolar, is up to 12cm, diameter about 1cm, it is tapering to tip.Seed is up to 2cm, about 3mm wide, white thin,tough silk matter kind hair of the seed tool up to 3cm.Flower Month phase 8-10, the fruiting period 9-12 months.Record in dictionary of medicinal plant.
Rattan is secondary：For Apocynaceae deer horn Calamus vegetable hair leaf rattan is secondary：Root, the stem of Chonemorpha valvata Chatt And stem skin.Whole year can adopt, and clean, and dry.【Nature and flavor】It is sweet；Slight bitter；Slightly warm in nature；Mild toxicity.【Indication】Dispelling, collateral-activating；Only Blood.Main rheumatic arthritis；Fracture；Traumatism and bleeding.【Former phytomorph】Sturdy woody climber.Sprout is by yellow pubescence, Quan Lin Has abundant milk.Leaf opposite, width egg shape or subcircular, 15-30cm long, 10-20cm wide, tip are suddenly sharp or perfectly round, base portion circle Shape, blade back is by pubescence；Vein is obvious.Basidixed cyme, flower pale red；Calyx 5 is split to base portion, and sliver valvate is arranged, Inner face base portion has dentation body of gland；The nearly pin disk like high of corolla, tube inner face is covered to the right by close pubescence, sliver；Stamen is born in Tube middle part, flower pesticide arrow shaped, filigree is by micro- pubescence；Floral disc ring-type, tip is shallow to be split；Constituted from raw carpel by 2 pieces in room, flower Post is thread, and tip is by microtriche.Follicle radish is twin parallel.Seed is flat, and tip has thin,tough silk matter kind hair long.Spring at florescence, summer, the fruiting period autumn, Winter.Record in dictionary of medicinal plant.
Trifolirhizin（Trifolirhizin）：CAS 6807-83-6, molecular formula C22H22O10, molecular weight 446.40.【Pharmacological action】There is antibacterial action.The antitumaous effect of this product is strong compared with other aglycons, but more weak than its dextrorotation.【Composition comes Source】Red clover Trifolium pratense, subprostrate sophora Sophora subprostrata ［ Syn.Sophora Tonkinensis ］.
Cucurbitacin L（ Cucurbitacin L）：CAS 1110-02-7, molecular formula C30H44O7, molecular weight 516.67.【It is raw Thing activity】Antitumor (animal Ehrlich ascites carcinoma in vivo, increase in life span 38%~42%）, cell toxicant（KB in Vitro, ED50=0.01~0.1ug/ml, HeLa in vitro, ED50=0.1ug/ml）.【Ingredient origin】Cowbind Bryonia alba, squirting cucumber Ecballium elaterium, without tendril watermelon Citrullus ecirrhosus, coloquintida Citrullus colocynthis。
Homoplantaginin（Homoplantaginin）：CAS 17680-84-1, molecular formula C22H22O11, molecular weight 462.40.【Pharmacological action】Tracheitis is controlled, antibechic, eliminating the phlegm is relievingd asthma, antibechic, eliminating the phlegm.【Ingredient origin】Labiate Common Sage Herb Herb.
3 chemical constitutions of bulk drug：
Trifolirhizin（Trifolirhizin）
Cucurbitacin L（ Cucurbitacin L）Homoplantaginin（Homoplantaginin）.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided it is a kind of effectively prevent and treat periodontitis pharmaceutical composition and Its preparation method.
The present invention adopts the following technical scheme that realization：
The composition and weight portion for being made the bulk drug of the pharmaceutical composition for preventing and treating periodontitis be：
The secondary 510-520 weight portions trifolirhizin 15- of Herba oxygraphis glacialis 530-540 weight portion Oblongleaf Heterostemma 525-530 weight portion rattans 20 weight portion cucurbitacin L10-13 weight portion Homoplantaginin 6-9 weight portions.
The pharmaceutical composition for preventing and treating periodontitis is preferably used in, is made up of the bulk drug of following weight portion：
The secondary weight portion cucurbitacin of 515 weight portion trifolirhizin 18 of the weight portion rattan of 535 weight portion Oblongleaf Heterostemma of Herba oxygraphis glacialis 528 The weight portion of L12 weight portions Homoplantaginin 8.
A kind of pharmaceutical composition for preventing and treating periodontitis, it is characterised in that pharmaceutical composition can be using the routine side of galenic pharmacy Method prepares piece agent or capsule or dripping pill.
A kind of pharmaceutical composition for preventing and treating periodontitis, it is characterised in that pharmaceutical composition is anti-with what chemical drugs or Chinese medicine were constituted Control periodontitis medicine.
A kind of preparation method of the pharmaceutical composition for preventing and treating periodontitis, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：The secondary 510- of Herba oxygraphis glacialis 530-540 weight portion Oblongleaf Heterostemma 525-530 weight portion rattans 520 weight portion trifolirhizin 15-20 weight portion cucurbitacin L10-13 weight portion Homoplantaginin 6-9 weight portions；
Preparation method：
（1）Secondary Oblongleaf Heterostemma, rattan, Herba oxygraphis glacialis, trifolirhizin, cucurbitacin L, Homoplantaginin are taken by bulk drug proportioning, is mixed, used The ethanol of weight percent concentration 36% takes as solvent in 25 DEG C of temperature extractions, and extraction time is 19 times, and each extraction time is 13 Hour, each solvent load is 27 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, Relative density 1.11 is concentrated into, is filtered, liquid is first washed with water, then use weight percent by DM133 large pore resin absorption columns The ethanol solution of specific concentration 21% elutes DM133 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 21%, returns Ethanol is received, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 17 times is carried every time The time is taken for 0.7 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP-850 large pore resin absorption columns, then with again Amount percent concentration 87% ethanol solution wash-out SP-850 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 87% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Preferred a kind of preparation method of the pharmaceutical composition for preventing and treating periodontitis, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：The secondary leaf of 515 weight portion three of the weight portion rattan of 535 weight portion Oblongleaf Heterostemma of Herba oxygraphis glacialis 528 The weight portion of 18 weight portion cucurbitacin L12 weight portions Homoplantaginin of beans red sandalwood glycosides 8；
Preparation method：
（1）Secondary Oblongleaf Heterostemma, rattan, Herba oxygraphis glacialis, trifolirhizin, cucurbitacin L, Homoplantaginin are taken by bulk drug proportioning, is mixed, used The ethanol of weight percent concentration 36% takes as solvent in 25 DEG C of temperature extractions, and extraction time is 19 times, and each extraction time is 13 Hour, each solvent load is 27 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, Relative density 1.11 is concentrated into, is filtered, liquid is first washed with water, then use weight percent by DM133 large pore resin absorption columns The ethanol solution of specific concentration 21% elutes DM133 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 21%, returns Ethanol is received, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 17 times is carried every time The time is taken for 0.7 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP-850 large pore resin absorption columns, then with again Amount percent concentration 87% ethanol solution wash-out SP-850 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 87% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method of the pharmaceutical composition for preventing and treating periodontitis, it is characterised in that pharmaceutical composition can use preparation Conventional method prepares piece agent or capsule or dripping pill.
A kind of preparation method of the pharmaceutical composition for preventing and treating periodontitis, it is characterised in that pharmaceutical composition and chemical drugs or in Medicine composition prevents and treats periodontitis medicine.
It is notable that pharmaceutical composition prevents and treats periodontitis effect.
Specific embodiment
Embodiment 1：Prevent and treat pharmaceutical composition of periodontitis and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of periodontitis be：Herba oxygraphis glacialis 535g Oblongleaf Heterostemma 528g rattans are secondary 515g trifolirhizin 18g cucurbitacin L12g Homoplantaginins 8g；
Preparation method：
（1）Secondary Oblongleaf Heterostemma, rattan, Herba oxygraphis glacialis, trifolirhizin, cucurbitacin L, Homoplantaginin are taken by bulk drug proportioning, is mixed, used The ethanol of weight percent concentration 36% takes as solvent in 25 DEG C of temperature extractions, and extraction time is 19 times, and each extraction time is 13 Hour, each solvent load is 27 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, Relative density 1.11 is concentrated into, is filtered, liquid is first washed with water, then use weight percent by DM133 large pore resin absorption columns The ethanol solution of specific concentration 21% elutes DM133 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 21%, returns Ethanol is received, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 17 times is carried every time The time is taken for 0.7 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP-850 large pore resin absorption columns, then with again Amount percent concentration 87% ethanol solution wash-out SP-850 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 87% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2：Prevent and treat pharmaceutical composition of periodontitis and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of periodontitis be：Herba oxygraphis glacialis 530g Oblongleaf Heterostemma 530g rattans are secondary 510g trifolirhizin 20g cucurbitacin L10g Homoplantaginins 9g；
Preparation method：
（1）Secondary Oblongleaf Heterostemma, rattan, Herba oxygraphis glacialis, trifolirhizin, cucurbitacin L, Homoplantaginin are taken by bulk drug proportioning, is mixed, used The ethanol of weight percent concentration 36% takes as solvent in 25 DEG C of temperature extractions, and extraction time is 19 times, and each extraction time is 13 Hour, each solvent load is 27 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, Relative density 1.11 is concentrated into, is filtered, liquid is first washed with water, then use weight percent by DM133 large pore resin absorption columns The ethanol solution of specific concentration 21% elutes DM133 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 21%, returns Ethanol is received, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 17 times is carried every time The time is taken for 0.7 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP-850 large pore resin absorption columns, then with again Amount percent concentration 87% ethanol solution wash-out SP-850 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 87% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3：Prevent and treat pharmaceutical composition of periodontitis and preparation method thereof
The composition and weight portion for preventing and treating the bulk drug of the pharmaceutical composition of periodontitis be：Herba oxygraphis glacialis 540g Oblongleaf Heterostemma 525g rattans are secondary 520g trifolirhizin 15g cucurbitacin L13g Homoplantaginins 6g；
Preparation method：
（1）Secondary Oblongleaf Heterostemma, rattan, Herba oxygraphis glacialis, trifolirhizin, cucurbitacin L, Homoplantaginin are taken by bulk drug proportioning, is mixed, used The ethanol of weight percent concentration 36% takes as solvent in 25 DEG C of temperature extractions, and extraction time is 19 times, and each extraction time is 13 Hour, each solvent load is 27 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, Relative density 1.11 is concentrated into, is filtered, liquid is first washed with water, then use weight percent by DM133 large pore resin absorption columns The ethanol solution of specific concentration 21% elutes DM133 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 21%, returns Ethanol is received, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 17 times is carried every time The time is taken for 0.7 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP-850 large pore resin absorption columns, then with again Amount percent concentration 87% ethanol solution wash-out SP-850 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 87% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4：The preparation of tablet
The pharmaceutical composition 422g of Example 1, adds starch 503g, mixes, and granulation is dried, plus microcrystalline cellulose 202g, stearic Sour magnesium 21g, mixes, and is pressed into 4500, obtains final product medicinal composition tablets.
Embodiment 5：The preparation of capsule
The pharmaceutical composition 330g of Example 2, adds starch 440g, mixes, and granulation is dried, whole grain, adds appropriate stearic acid Magnesium, mixes, and encapsulated 2100, obtains final product medicament composition capsule.
Embodiment 6：The preparation of dripping pill
Weigh (80 DEG C) heating of Macrogol 6000 220g water-baths and boil molten, add the pharmaceutical composition 11g of embodiment 3, fully stir Mix uniform, with atoleine as cooling agent, put glass tube（4*80cm）In, chilling temperature is 5 DEG C, and drip internal-and external diameter is 7.0/ 2.0 (mm/mm), drip is 2.0cm away from liquid level, and drop speed is optimum condition with every point 46 drop, and the cold of dripping pill surface is blotted with cotton Solidifying agent, obtains final product medicament composition dropping pills.
Experimental example 1：Prevent and treat the experimental study of periodontitis
1 data and method
1.1 physical data
The patient 24 of the periodontal disease that the court accepts for medical treatment in May, -2012 in May, 2011 is chosen, and excluded such as smoker, had system Property Disease, gestation, mammalian patient or in the recent period have gestation plan, every day use contain antibacterial, antibacterial and anti-inflammatory drug plain mouth Water patient.
Patient's inclusion criteria:1. age 18~65 years old；2. during Dentist is diagnosed as, severe periodontitis, and through traditional Chinese physician Diagnosis meets the patient of kidney deficiency fire type；3. every existing tooth of the full mouth of patient at least 16, chooses each 1 periodontal in two quadrants Bag is visited and examines depth (periodontical pocket depth, PPD) not less than 5mm, clinical attachment loss (clinical At-tachm ent loss, CAL) (III degree of agomphiasis in test may be pulled out for index tooth for tooth of suffering from not less than 3mm Except tooth)；4. informed consent；5. without the system medical history such as blood, heart, immune；6. Antibiotics medicine was not used in 2 weeks； 7. the periodontal treatment of system was not received in 3 months；8. immunomodulator or immunodepressant were not used in 3 months.
Patient is randomly divided into two groups by 28 patients according to the method for digital random, observation group 12, wherein man 6, Female 6, the age be 33~73 years old, average age be (46.0 ± 6.0) year, average course of disease (12.2 ± 5.0) d；Control group 12 Example, wherein man 6, female 6, the age be 34~72 years old, average age be (46.3 ± 6.0) year, average course of disease (13.1 ± 5.9) d.The basic datas such as two groups of classification of patient age, sex, the course of disease and disease compare no difference of science of statistics, P ＞ 0.05, data With comparativity.
1.2 methods
The oral conditions of selected patient are checked, clinical indexes are recorded:SBI (sulcus bleeding Index, SBI), Movable degree (mobility de-gree, MD), oral pocket visit examine depth (periodontical pocket Depth, PPD) it is not less than 5mm, clinical attachment loss (clinical attachment loss, CAL), row is complete after inspection is finished Scaling on mouthful ultrasonic gum, two groups of patients carry out oral hygiene guidance, and antibiotic therapy, including metronidazole 0.2g, and daily 3 It is secondary；Amoxicillin 0.5g, three times a day.If there is penicillin anaphylaxis, Amoxicillin is changed to azithromycin 0.5g, once a day.See Group is examined on this basis according to combination of oral medication（The pharmaceutical composition of embodiment 1）Treatment, each 1g, 3 times a day.
1.3 observation index
Two groups of patients underwent's baselines are checked.SBI (sulcus bleed-ing index, SBI), Movable degree (mobility degree, MD), PPD, CAL for being recorded by 6 sites.After baseline is checked, two groups of patients carry out dental pattern gum Upper scaling, two index teeth and its front and rear each 1 phase adjacent teeth carry out subgingival debridement, and row oral hygiene instyuctions simultaneously, provide medicine Thing, direction of medication usage method.
1.4 medicament composing prescriptions and usage
Pharmaceutical composition and usage:The pharmaceutical composition of embodiment 1,1g decoctings 30min (slow fire) about 20mL, orally, 3 times a day. All medicines are 1 course for the treatment of in 1 week, take medicine continuously 2 courses for the treatment of.
1.5 efficacy determinations
It is almost recovered:SBI reduces more than 2 grades, and PPD, CAL reduce more than 1mm, or 2 degree of MD reductions.It is effective:SBI reduces 1 grade More than, PPD, CAL reduce more than 0.5mm, or 1 degree of MD reductions.It is invalid:Above-mentioned symptom and index are not improved.
1.6 statistical procedures
All data use SPSS17.0 software analysis.Measurement data is represented using means standard deviation (x ± s), entered between group Row t is checked, and enumeration data uses χ2Inspection.Set significance as P ＜ 0.05.
2 results
2.1 two groups of comparings of patients after curative treatment
The results are shown in Table 1.
1 two groups of patients after curative treatment of table compare ［ example (%) ］
Group Number of cases Recovery from illness Effectively It is invalid It is total effective
Observation group 12 6 5 1 11(91.67)*
Control group 12 4 4 4 8(66.67)
Note:Compared with control group, * P ＜ 0.05.
Subjective symptoms compares after 2.2 two groups of patient's treatments
After therapy of combing traditional Chinese and Western medicine, patient's swelling and aching of gum, bleeding gums and halitosis disappearance rate are above control group, two for observation group Group is compared, and difference has statistical significance, P ＜ 0.05.
Gingivitis indices and tooth mobility situation compare before and after 2.3 two groups of patient's treatments
After positive treatment, the gingivitis indices and tooth mobility situation of two groups of patients take a favorable turn, but observation group significantly by In control group, two groups are compared, and difference has statistical significance, P ＜ 0.05.
2.4 two groups of Patients on Recurrence rates compare
Two groups of Zhou Hou observation groups 1 case relapseds of follow-up of patients 4~8, recurrence rate is 8.33%, and control group recurs 4, and recurrence rate is 33.33%, two groups are compared, and difference has statistical significance, P ＜ 0.05.Refer to table 4.
Recurrence compares after 4 two groups of table patient 4~8 weeks
Group Number of cases Recurrence number of cases Recurrence rate (%)
Observation group 12 1 8.33*
Control group 12 4 33.33
Note:Compared with control group, * P ＜ 0.05.
2.5 two groups of adverse reactions of patients compare
Control group is significantly higher than the adverse reaction rate of observation group during treatment, and two groups are compared, and difference has statistical significance, P ＜ 0.05.

Claims (8)

1. a kind of pharmaceutical composition for preventing and treating periodontitis, it is characterised in that be made the composition and weight of the bulk drug of the pharmaceutical composition Measuring part is：
The secondary 510-520 weight portions trifolirhizin 15- of Herba oxygraphis glacialis 530-540 weight portion Oblongleaf Heterostemma 525-530 weight portion rattans 20 weight portion cucurbitacin L10-13 weight portion Homoplantaginin 6-9 weight portions.
2. a kind of pharmaceutical composition for preventing and treating periodontitis according to claim 1, it is characterised in that be made the pharmaceutical composition Bulk drug composition and weight portion be：
The secondary weight portion cucurbitacin of 515 weight portion trifolirhizin 18 of the weight portion rattan of 535 weight portion Oblongleaf Heterostemma of Herba oxygraphis glacialis 528 The weight portion of L12 weight portions Homoplantaginin 8.
3. a kind of pharmaceutical composition for preventing and treating periodontitis according to claim 1, it is characterised in that pharmaceutical composition can be adopted Piece agent or capsule or dripping pill are prepared with the conventional method of galenic pharmacy.
4. a kind of pharmaceutical composition for preventing and treating periodontitis according to claim 1, it is characterised in that pharmaceutical composition and chemistry What medicine or Chinese medicine were constituted prevents and treats periodontitis medicine.
5. a kind of preparation method of the pharmaceutical composition for preventing and treating periodontitis, it is characterised in that prepare as follows：
The secondary 510-520 weight portions trifolirhizin 15- of Herba oxygraphis glacialis 530-540 weight portion Oblongleaf Heterostemma 525-530 weight portion rattans 20 weight portion cucurbitacin L10-13 weight portion Homoplantaginin 6-9 weight portions；
Preparation method：
（1）Secondary Oblongleaf Heterostemma, rattan, Herba oxygraphis glacialis, trifolirhizin, cucurbitacin L, Homoplantaginin are taken by bulk drug proportioning, is mixed, used The ethanol of weight percent concentration 36% takes as solvent in 25 DEG C of temperature extractions, and extraction time is 19 times, and each extraction time is 13 Hour, each solvent load is 27 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, Relative density 1.11 is concentrated into, is filtered, liquid is first washed with water, then use weight percent by DM133 large pore resin absorption columns The ethanol solution of specific concentration 21% elutes DM133 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 21%, returns Ethanol is received, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 17 times is carried every time The time is taken for 0.7 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP-850 large pore resin absorption columns, then with again Amount percent concentration 87% ethanol solution wash-out SP-850 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 87% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. a kind of preparation method of the pharmaceutical composition for preventing and treating periodontitis according to claim 5, it is characterised in that by as follows It is prepared by step：
The secondary weight portion cucurbitacin of 515 weight portion trifolirhizin 18 of the weight portion rattan of 535 weight portion Oblongleaf Heterostemma of Herba oxygraphis glacialis 528 The weight portion of L12 weight portions Homoplantaginin 8；
Preparation method：
（1）Secondary Oblongleaf Heterostemma, rattan, Herba oxygraphis glacialis, trifolirhizin, cucurbitacin L, Homoplantaginin are taken by bulk drug proportioning, is mixed, used The ethanol of weight percent concentration 36% takes as solvent in 25 DEG C of temperature extractions, and extraction time is 19 times, and each extraction time is 13 Hour, each solvent load is 27 times of bulk drug gross weight, is filtered, and obtains dregs of a decoction A and extract solution A, and extract solution A reclaims ethanol, Relative density 1.11 is concentrated into, is filtered, liquid is first washed with water, then use weight percent by DM133 large pore resin absorption columns The ethanol solution of specific concentration 21% elutes DM133 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 21%, returns Ethanol is received, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 46% as solvent, heating and refluxing extraction 17 times is carried every time The time is taken for 0.7 hour, each solvent load is 22 times of dregs of a decoction A weight, and filtration obtains dregs of a decoction B and extract solution B, and extract solution B is returned Ethanol is received, relative density 1.04 is concentrated into, filtered, liquid is first washed with water by SP-850 large pore resin absorption columns, then with again Amount percent concentration 87% ethanol solution wash-out SP-850 large pore resin absorption columns, collect the ethanol elution of weight percent concentration 87% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. a kind of preparation method of the pharmaceutical composition for preventing and treating periodontitis according to claim 5, it is characterised in that medicine group Compound can prepare piece agent or capsule or dripping pill using the conventional method of galenic pharmacy.
8. a kind of preparation method of the pharmaceutical composition for preventing and treating periodontitis according to claim 5, it is characterised in that medicine group Compound prevents and treats periodontitis medicine with chemical drugs or Chinese medicine composition.
CN201611133168.5A 2016-12-10 2016-12-10 A kind of pharmaceutical composition for preventing and treating periodontitis Withdrawn CN106728036A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611133168.5A CN106728036A (en) 2016-12-10 2016-12-10 A kind of pharmaceutical composition for preventing and treating periodontitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611133168.5A CN106728036A (en) 2016-12-10 2016-12-10 A kind of pharmaceutical composition for preventing and treating periodontitis

Publications (1)

Publication Number Publication Date
CN106728036A true CN106728036A (en) 2017-05-31

Family

ID=58875044

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611133168.5A Withdrawn CN106728036A (en) 2016-12-10 2016-12-10 A kind of pharmaceutical composition for preventing and treating periodontitis

Country Status (1)

Country Link
CN (1) CN106728036A (en)

Similar Documents

Publication Publication Date Title
CN102139030B (en) Oral Chinese herbal preparation for treating gingivitis and preparation method thereof
CN101703684B (en) Medicament for treating allergic purpura and preparation method thereof
CN106668092A (en) Pharmaceutical composition for treating periodontitis and preparation method thereof
CN106668348A (en) Pharmaceutical composition for treating diabetic retinopathy
CN114712478B (en) Traditional Chinese medicine composition for treating intestinal diseases, preparation and preparation method thereof
CN105287921A (en) Medicinal composition for treating gastric cancer and preparation method thereof
CN106728036A (en) A kind of pharmaceutical composition for preventing and treating periodontitis
CN118477149B (en) Traditional Chinese medicine composition for treating pharyngitis
CN100361684C (en) Chinese medicinal preparation for treating decayed teeth and preparation process thereof
CN105287863A (en) Pharmaceutical composition for curing DN (Diabetic Nephropathy) and preparation method of pharmaceutical composition
CN105943860A (en) Medicine preparation for treating diabetes mellitus and preparation method thereof
CN117442698A (en) Application of traditional Chinese medicine composition in preparation of medicines for treating exopathogenic pestilential qi
CN106728895A (en) A kind of pharmaceutical composition for treating periodontitis
CN106727790A (en) A kind of pharmaceutical composition for treating tonsillitis
CN114949105A (en) Medicinal toothpaste for preventing and treating oral mucositis caused by radiotherapy and chemotherapy
CN106581433A (en) Medicine composition for preventing and treating periodontitis
CN106852948A (en) A kind of pharmaceutical composition for treating canker sore
CN106581434A (en) Pharmaceutical composition for prevention and treatment of periodontitis and preparation method thereof
CN106581104A (en) Medicinal composition for treating periodontitis
CN106581435A (en) Medicine composition for preventing and treating periodontitis and preparation method thereof
CN106728474A (en) Treat the pharmaceutical composition of thyroid disease
CN106620270A (en) Pharmaceutical composition for treating periodontitis
CN105267401A (en) Pharmaceutical composition for treating child cough and preparation method thereof
CN106692578A (en) Pharmaceutical composition for preventing and treating oral ulcer and preparation method of pharmaceutical composition
CN106619771A (en) Medicine compositionc for preventing and treating hysteromyoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20170531